"After five years of Simon Ehrenfeld, and a long history of a downward spiralling share price, isn't it time for change?"Who have you got, and what will he bring?And why are you hiding this sensational new CEO from the shareholders?
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%